{"id":164723,"date":"2023-01-10T00:22:18","date_gmt":"2023-01-10T05:22:18","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/vyne-therapeutics-announces-first-vitiligo-patient-dosed-in-phase-1a-b-clinical-trial-of-novel-bet-inhibitor-vyn201\/"},"modified":"2024-08-18T11:46:43","modified_gmt":"2024-08-18T15:46:43","slug":"vyne-therapeutics-announces-first-vitiligo-patient-dosed-in-phase-1a-b-clinical-trial-of-novel-bet-inhibitor-vyn201","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/vyne-therapeutics-announces-first-vitiligo-patient-dosed-in-phase-1a-b-clinical-trial-of-novel-bet-inhibitor-vyn201.php","title":{"rendered":"VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a\/b Clinical Trial of Novel BET Inhibitor VYN201"},"content":{"rendered":"<p><![CDATA[First patient dosed follows swiftly from IND clearance and enrollment of first healthy volunteers in Phase 1a portion of study in November]]><\/p>\n<p>Go here to see the original:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/01\/09\/2585652\/0\/en\/VYNE-Therapeutics-Announces-First-Vitiligo-Patient-Dosed-in-Phase-1a-b-Clinical-Trial-of-Novel-BET-Inhibitor-VYN201.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a\/b Clinical Trial of Novel BET Inhibitor VYN201\">VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a\/b Clinical Trial of Novel BET Inhibitor VYN201<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Go here to see the original: VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a\/b Clinical Trial of Novel BET Inhibitor VYN201 <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/vyne-therapeutics-announces-first-vitiligo-patient-dosed-in-phase-1a-b-clinical-trial-of-novel-bet-inhibitor-vyn201.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-164723","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164723"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=164723"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164723\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=164723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=164723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=164723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}